Two Pfizer and BioNTech Covid-19 vaccine boosters updated to target the Omicron variant show a substantially higher immune response than the current Covid-19 vaccine, the companies said Saturday.
The companies tested a vaccine that targets Omicron BA.1 subvariant and bivalent booster — which targets two strains — that includes the current Pfizer/BioNTech Covid-19 vaccine and a vaccine candidate that targets Omicron.
The study looked at two different dose levels — 30 micrograms and 60 micrograms — in more than 1,200 adults age 56 and older. The current primary and booster dosage for this age group is 30 micrograms. The study showed that, across both dose levels, a fourth booster with the Omicron-modified vaccine candidates resulted in a substantially higher immune response against the variant.